396 related articles for article (PubMed ID: 37373103)
1. Clinical Potential of Hydrogen Sulfide in Peripheral Arterial Disease.
Bechelli C; Macabrey D; Deglise S; Allagnat F
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373103
[TBL] [Abstract][Full Text] [Related]
2. Clinical Use of Hydrogen Sulfide to Protect Against Intimal Hyperplasia.
Macabrey D; Longchamp A; Déglise S; Allagnat F
Front Cardiovasc Med; 2022; 9():876639. PubMed ID: 35479275
[TBL] [Abstract][Full Text] [Related]
3. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
Bonaca MP; Gutierrez JA; Creager MA; Scirica BM; Olin J; Murphy SA; Braunwald E; Morrow DA
Circulation; 2016 Mar; 133(10):997-1005. PubMed ID: 26826179
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of Peripheral Artery Disease and Polyvascular Disease.
Aday AW; Matsushita K
Circ Res; 2021 Jun; 128(12):1818-1832. PubMed ID: 34110907
[TBL] [Abstract][Full Text] [Related]
5. Effect of hydrogen sulfide on restenosis of peripheral arteries after angioplasty.
Ma B; Liang G; Zhang F; Chen Y; Zhang H
Mol Med Rep; 2012 Jun; 5(6):1497-502. PubMed ID: 22470131
[TBL] [Abstract][Full Text] [Related]
6. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(18):1-88. PubMed ID: 23074395
[TBL] [Abstract][Full Text] [Related]
7. Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Di Minno G; Spadarella G; Cafaro G; Petitto M; Lupoli R; Di Minno A; de Gaetano G; Tremoli E
Ann Med; 2014 Nov; 46(7):475-89. PubMed ID: 25045928
[TBL] [Abstract][Full Text] [Related]
8. Peripheral artery disease: Update on etiology, pathophysiology, diagnosis and treatment.
Mandaglio-Collados D; Marín F; Rivera-Caravaca JM
Med Clin (Barc); 2023 Oct; 161(8):344-350. PubMed ID: 37517924
[TBL] [Abstract][Full Text] [Related]
9. Hydrogen sulfide in pharmacology and medicine--An update.
Bełtowski J
Pharmacol Rep; 2015 Jun; 67(3):647-58. PubMed ID: 25933982
[TBL] [Abstract][Full Text] [Related]
10. Atherosclerosis and the Hydrogen Sulfide Signaling Pathway - Therapeutic Approaches to Disease Prevention.
Wang ZJ; Wu J; Guo W; Zhu YZ
Cell Physiol Biochem; 2017; 42(3):859-875. PubMed ID: 28641276
[TBL] [Abstract][Full Text] [Related]
11. Hydrogen sulfide and cardioprotection--Mechanistic insights and clinical translatability.
Salloum FN
Pharmacol Ther; 2015 Aug; 152():11-7. PubMed ID: 25913517
[TBL] [Abstract][Full Text] [Related]
12. Hydrogen sulfide releasing hydrogel for alleviating cardiac inflammation and protecting against myocardial ischemia-reperfusion injury.
Zhang Q; Wang L; Yin Y; Shen J; Xie J; Yuan J
J Mater Chem B; 2022 Jul; 10(28):5344-5351. PubMed ID: 35792619
[TBL] [Abstract][Full Text] [Related]
13. The effect of lifestyle and risk factor modification on occlusive peripheral arterial disease outcomes: standard healthcare vs structured programme-for a randomised controlled trial protocol.
Elfghi M; Jordan F; Dunne D; Gibson I; Jones J; Flaherty G; Sultan S; Tawfick W
Trials; 2021 Feb; 22(1):138. PubMed ID: 33581715
[TBL] [Abstract][Full Text] [Related]
14. Targeting hydrogen sulfide as a promising therapeutic strategy for atherosclerosis.
Xu S; Liu Z; Liu P
Int J Cardiol; 2014 Mar; 172(2):313-7. PubMed ID: 24491853
[TBL] [Abstract][Full Text] [Related]
15. Effects of a novel hydrogen sulfide prodrug in a porcine model of acute limb ischemia.
Rushing AM; Donnarumma E; Polhemus DJ; Au KR; Victoria SE; Schumacher JD; Li Z; Jenkins JS; Lefer DJ; Goodchild TT
J Vasc Surg; 2019 Jun; 69(6):1924-1935. PubMed ID: 30777693
[TBL] [Abstract][Full Text] [Related]
16. Contemporary Medical Management of Peripheral Artery Disease.
Bonaca MP; Hamburg NM; Creager MA
Circ Res; 2021 Jun; 128(12):1868-1884. PubMed ID: 34110910
[TBL] [Abstract][Full Text] [Related]
17. PAD in women: the ischemic continuum.
Pollak AW
Curr Atheroscler Rep; 2015 Jun; 17(6):513. PubMed ID: 25939674
[TBL] [Abstract][Full Text] [Related]
18. Protective Actions of H2S in Acute Myocardial Infarction and Heart Failure.
Donnarumma E; Trivedi RK; Lefer DJ
Compr Physiol; 2017 Mar; 7(2):583-602. PubMed ID: 28333381
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic Therapy for Peripheral Artery Disease: Recent Advances.
Hussain MA; Al-Omran M; Creager MA; Anand SS; Verma S; Bhatt DL
J Am Coll Cardiol; 2018 May; 71(21):2450-2467. PubMed ID: 29793635
[TBL] [Abstract][Full Text] [Related]
20. Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT.
Inglis SC; Bebchuk J; Al-Suhaim SA; Case J; Pfeffer MA; Solomon SD; Hou YR; Pitt B; Dargie HJ; Ford I; Kjekshus J; Zannad F; Dickstein K; McMurray JJ
Int J Cardiol; 2013 Sep; 168(2):1094-101. PubMed ID: 23194780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
